FLOVENT DISKUS POWDER

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

FLUTICASONE PROPIONATE

Dostupné z:

GLAXOSMITHKLINE INC

ATC kód:

R03BA05

INN (Medzinárodný Name):

FLUTICASONE

Dávkovanie:

250MCG

Forma lieku:

POWDER

Zloženie:

FLUTICASONE PROPIONATE 250MCG

Spôsob podávania:

INHALATION

Počet v balení:

60 DOSES

Typ predpisu:

Prescription

Terapeutické oblasti:

ADRENALS

Prehľad produktov:

Active ingredient group (AIG) number: 0124685003; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2001-07-04

Súhrn charakteristických

_ _
_Page 1 of 57_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
FLOVENT HFA
fluticasone propionate inhalation aerosol
50, 125, and 250 mcg/metered dose
PR
FLOVENT DISKUS
fluticasone propionate powder for inhalation
100, 250, and 500 mcg/blister
Corticosteroid for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Initial Approval:
July 31, 1995
Date of Revision:
March 1, 2021
Submission Control No: 243742
_©_
_2021 GSK group of companies or its licensor _
_AEROCHAMBER PLUS is a trademark owned by Trudell Medical
International. All other trademarks are owned by or licensed _
_to the GSK group of companies. _
_ _
_Page 2 of 57_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE
NOT LISTED.
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4
1
INDICATIONS
....................................................................................................................4
1.1 Pediatrics
........................................................................................................................4
1.2 Geriatrics
........................................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................4
4 DOSAGE AND ADMINISTRATION .......................................................................................4
4.1 Dosing Considerations
...................................................................................................5
4.2 Recommended Dose and Dosage Adjustment
...............................................................5
4.4 Administration
...............................................................................................................